Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
Cardiac resynchronization therapy (CRT) is a treatment for heart failure in patients who also
suffer from ventricular dyssynchrony, a form of uncoordinated contraction of the ventricle
(lower pumping chamber of the heart). In the past decade, CRT has become an established
treatment for heart failure patients who are in normal rhythm, called sinus rhythm. An
important subset of heart failure patients are those with atrial fibrillation (AF), who make
up around 1 in 4 HF patients, and are over-represented amongst HF patients with more advanced
symptoms. In heart failure patients with AF, CRT has proven not to be as effective as in
sinus rhythm, due to competition between beats generated by the CRT device and beats
conducted from the heart's own electrical conduction system. In the current study, we aim to
test the hypothesis that ablating the AV node, which controls electrical conduction from the
heart's atria (top chamber) to its ventricles (lower chambers), will improve survival and
heart failure symptoms in CRT patients with co-existent AF. The results are important,
because they will provide a way of passing on the benefits of CRT, such as improved survival,
less heart failure symptoms, and better quality of life, to heart failure patients who also
suffer from AF.
Phase:
N/A
Details
Lead Sponsor:
University of Adelaide
Collaborators:
Abbott Medical Devices Boston Scientific Corporation Medtronic St. Jude Medical